Key Points
- Director Jeffrey Stein purchased 50,000 shares of IDEAYA on March 2 at an average price of $32.96 (about $1,648,000), now directly owning 54,281 shares after the transaction as disclosed in an SEC filing.
- IDYA trades around $33 with a market cap of about $2.9B; the company beat last quarter's revenue and EPS estimates (revenue $21.75M, EPS -$0.94), revenue was up 55.7% YoY, and analysts carry a consensus "Moderate Buy" rating with a $48.69 price target.
IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) Director Jeffrey Stein purchased 50,000 shares of IDEAYA Biosciences stock in a transaction that occurred on Monday, March 2nd. The shares were acquired at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the acquisition, the director directly owned 54,281 shares of the company's stock, valued at $1,789,101.76. This trade represents a 1,167.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
IDEAYA Biosciences Stock Up 2.6%
IDYA opened at $33.04 on Tuesday. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $39.28. The business has a 50 day moving average of $33.99 and a 200-day moving average of $30.97. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -25.22 and a beta of 0.09.
IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.03) by $0.09. The business had revenue of $21.75 million during the quarter, compared to the consensus estimate of $5.95 million. During the same quarter last year, the company posted ($1.49) EPS. The firm's revenue was up 55.7% on a year-over-year basis. As a group, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on IDYA. Truist Financial raised their price objective on shares of IDEAYA Biosciences from $59.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday, January 6th. Weiss Ratings restated a "sell (d-)" rating on shares of IDEAYA Biosciences in a research note on Thursday, January 22nd. Citigroup increased their price objective on IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a "buy" rating in a research report on Thursday, February 19th. Royal Bank Of Canada reissued an "outperform" rating and set a $49.00 target price on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Wednesday, February 18th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.69.
Check Out Our Latest Stock Analysis on IDEAYA Biosciences
Hedge Funds Weigh In On IDEAYA Biosciences
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its holdings in shares of IDEAYA Biosciences by 171.1% during the 4th quarter. Farther Finance Advisors LLC now owns 919 shares of the company's stock worth $32,000 after acquiring an additional 580 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of IDEAYA Biosciences in the 3rd quarter valued at $38,000. ANTIPODES PARTNERS Ltd boosted its holdings in shares of IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company's stock valued at $40,000 after purchasing an additional 380 shares in the last quarter. Abich Financial Wealth Management LLC bought a new position in shares of IDEAYA Biosciences in the 3rd quarter valued at $58,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of IDEAYA Biosciences during the 2nd quarter worth $61,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.
IDEAYA Biosciences Company Profile
(
Get Free Report)
IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA's pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.
Central to IDEAYA's approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
